« | Home | »

Launching Next Generation Oncology Products: Evolving Strategies in a Payors Market–Aarkstore Enterprise

By Health Care Info | February 11, 2010



Health care has led us to search and find valuable information for you. The issue of health care is increasingly in vogue and that is why our efforts have led to find out more about this subject. In our endeavour to find such data we are now able to present this content that we hope will be of total satisfaction. Today we encountered this content relating to health care issues and we have made available. The content is entitled: france healthcare. And you can see it below.
Aarkstore announce a new report “Launching Next-generation oncology products report: Evolving strategies in the market cost” through his extensive collection of market research. The emergence of a new wave of oncology products is one of the most dramatic developments in the pharmaceutical market in the last ten years. Both large and small companies to make unprecedented investment in oncology R & D in an effort to emulate the success of new targeted therapies like Herceptin, Avastin, Gleevec, Nexavar and Erbitux. Underlying that success has been real improvements in therapeutic options for a range of cancers, including clear cut steps to survive in the areas of poor prognosis, such as kidney cancer (eg, Sutent), effective therapies for genetic subgroups are defined, for widespread malignancies ) (Herceptin in breast cancer, and innovations that have changed into a fatal chronic diseases (Gleevec for chronic) myeloid leukemia. At the same time, the success has a price. Not the oncology market getting more crowded, the bar for the differentiation in a category where many products that are on the same disease mechanisms, but the premium price charged for newer therapies, stretching spending on health care. Increasingly, anticancer drugs lose their special status guarantees that the host at any price and get the same cost-benefit scrutiny as other components of health care. In today’s market are the payer, oncology companies forced to reassess their strategies and build a compelling value equation for their products that meet the needs of a whole range of actors that satisfy all their own agenda. And they must do so while looking for a way to have to draw on R & D costs of niche products without the patient volume, the blockbuster brands in the past driven. The main results of Global sales of cancer drugs is expected to increase at an average annual growth rate of 12-15% compared to 2008 and has U.S. $ 75-80 billion 2012th Agencies that would nearly double the forecasted growth rate for the pharmaceutical market as a whole during the same period. At the same time the growth of the category is expected that over the next five years, slowly progressing, with a diminishing contribution of the top oncology markets – the U.S., France, Germany, Italy, Britain and Spain. These countries accounted for 71% of oncology product sales worldwide in 2007. By 2012, however, have their share of total sales, up to 65%. Increased cost-sensitivity between the payer market and pushing the loss of the special status of cancer, ‘the market is a lot of Oncology challenge for established companies and new competitors in the coming years to make. Key features of this report, detailed analysis of the new drivers of growth in the global oncology market. Overview of the cost pressures on health and the growing use of Health Technology Assessment, the complicated barriers for new anticancer drugs. Analysis of the NICE decisions on premium-priced oncology products, the wider political context in which these decisions are taken, and what they could mean for oncology players in other markets. Detailed study how a multi-faceted value proposition needs to be built for new cancer therapies, including survival benefit, cost-effective and more personal elements such as quality of life. This report manages to detailed understanding of the new growth drivers in the world oncology market and the emerging threats to continued growth an insight into the health systems to develop in their efforts to keep inflation and the costs, how these changes pose a great challenge for oncology market growth. Compare understand approaches to health technology assessment in key markets like the UK and the USA like this raising the bar to entry for new oncology products. Detailed insight into the different components of the value of allowing it to carve niches for new cancer therapies in the new payer-dominated environment. Discover How will the market for oncology products in the years to 2012 and beyond? How has changed the treatment paradigm in oncology in terms of targeted therapies, niche information and payers influence? What are the government, HTA agencies, health insurers and other opinion payers in major markets like the UK and the U.S. do to budgetary constraints, to medicines in general and new oncology products in particular? For more information, please visit: http://www. aarkstore. com/reports/Launching-Next-Generation-Oncology-Products-Evolving-Strategies-in-a-Payors-Market-34832. htmlOr email aarkstore to press @. com or call +919272852585 Special offer until 31 December 2009

Related posts:

  1. France Patient Monitoring Market Outlook to 2016—Aarkstore Enterprise Market Research Aggregation France Patient Monitoring Market Outlook 2016Summary New Report ‘France Patient...
  2. Global Heart Valve Market 2008-2012–Aarkstore Enterprise Market Research Aggregation Growth in the aging population (generally 60 and above) is...
  3. Global Heart Valve Market 2008-2012—-Aarkstore Enterprise Growth in the aging population (generally 60 and above) is...
  4. Rheumatoid Arthritis – Drug Pipeline Analysis And Market Forecasts To 2015—Aarkstore Enterprise Market Research Aggregation Rheumatoid arthritis – Drugs Pipeline Analysis and Market Forecasts to...
  5. France In Vitro Diagnostics Investment Opportunities, Analysis And Forecasts To 2015—Aarkstore Enterprise Market Research Aggregation France In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to...

Related posts brought to you by Yet Another Related Posts Plugin.

Topics: France Healthcare | No Comments »

Comments